Institut Paoli-calmettes

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This phase II trial is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy can improve outcomes for people with HER2-negative inflammatory breast cancer, a rare and aggressive type. About 52 participants will receive either chemo alone …

This study is collecting blood and tumor samples from 300 people suspected of having ovarian, endometrial, or cervical cancer. Researchers will analyze the samples to find genetic changes that might predict how the cancer behaves. The goal is to better understand these cancers, n…

This study is looking at two substances in the blood, called MMP2 and MMP9, to see if they can predict how well certain drugs work for people with advanced kidney cancer. Researchers will measure these markers in 50 patients who are starting treatment with Sunitinib or Pazopanib,…

This study collects tumor and blood samples from 241 women with HR+/HER2- advanced breast cancer before and after treatment with ribociclib (Kisqali) plus hormone therapy. Researchers will analyze DNA and RNA changes to find markers that predict who responds well and who develops…